Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05426031 · ClinicalTrials.gov registry record · Phase 4
Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass
A Phase 4 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 4
- Development phase
- 130
- Enrollment target
NCT05426031 is a Phase 4 study that has completed, run by University of Miami. The registered enrollment target is 130 participants.
The verdict
NCT05426031, a Phase 4 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two different dosing strategies of a drug named protamine.
Interventions
- DRUG Protamine fixed dose
- DRUG Protamine ratio dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2022-06-28 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05426031
The ClinicalTrials.gov registry entry for NCT05426031 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Protamine fixed dose is the first listed.
NCT05426031 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05426031 about?
NCT05426031 is a clinical study titled "Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass". The purpose of this study is to compare two different dosing strategies of a drug named protamine.
What is the current status of trial NCT05426031?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 130 participants. The study started on 2022-06-28. Estimated completion is 2023-06-01.
What interventions are being tested in trial NCT05426031?
The interventions under investigation include: Protamine fixed dose (DRUG), Protamine ratio dose (DRUG).
Who is sponsoring clinical trial NCT05426031?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.